Market Newsdesk

CINCINNATI, Sept. 29, 2022 (GLOBE NEWSWIRE) — Phillips Edison & Company, Inc. (Nasdaq: PECO) (“PECO”), one of the nation’s largest owners and operators of grocery-anchored neighborhood shopping centers, will announce its third quarter earnings results on Thursday, November 3, 2022, after the market close. PECO’s earnings release and supplemental information package will be posted on the Investor Relations section of the Company’s website at https://investors.phillipsedison.com. Chairman and Chief Executive Officer Jeff Edison, President Devin Murphy, and Chief Financial Officer John Caulfield will host an earnings conference call to discuss results, which will be webcast on Friday, November 4, 2022, at 12:00 p.m. ET.

A webcast replay will be available approximately one hour after the conclusion of the presentation using the same link. Webcasts are archived on PECO’s Investor Relations website.

Connect with PECO:

• For additional information, please visit https://www.phillipsedison.com/
• Follow PECO on:
• Twitter at https://twitter.com/PhillipsEdison
• Facebook at https://www.facebook.com/phillipsedison.co
• Instagram at https://www.instagram.com/phillips.edison/; and
• Find PECO on LinkedIn at https://www.linkedin.com/company/phillipsedison&company

About Phillips Edison & Company

Phillips Edison & Company, Inc. is one of the nation’s largest owners and operators of omni-channel grocery-anchored neighborhood shopping centers. Founded in 1991, PECO has generated strong results through its vertically-integrated operating platform and national footprint of well-occupied shopping centers. PECO’s centers feature a mix of national and regional retailers providing necessity-based goods and services in fundamentally strong markets throughout the United States. PECO’s top grocery anchors include Kroger, Publix, Ahold Delhaize, and Albertsons. As of June 30, 2022, PECO manages 289 shopping centers, including 269 wholly-owned centers comprising 30.9 million square feet across 31 states, and 20 shopping centers owned in one institutional joint venture. PECO is exclusively focused on creating great omni-channel, grocery-anchored shopping experiences and improving communities, one neighborhood shopping center at a time.

Investors:

Phillips Edison & Company, Inc.
[email protected]

Kimberly Green, Vice President of Investor Relations
(513) 692-3399
[email protected]

Stephanie Hout, Director of Investor Relations
(513) 746-2594
[email protected]

Source: Phillips Edison & Company, Inc.

COAST SALISH TERRITORY, Sept. 29, 2022 (GLOBE NEWSWIRE) — The First Nations Major Projects Coalition (FNMPC) is pleased to announce Cenovus Energy Inc. (Cenovus) as a new member of its Sustaining Partners Program. The program furthers FNMPC’s ability to advance relationships between its members and the private sector on issues of mutual interest. Cenovus, along with existing program members CIBC, Colliers Project Leaders, COWI, Gowling WLG, IBI Group and New Gold Inc., will benefit from an exclusive relationship with FNMPC that will be focused on advancing progressive Indigenous business initiatives between the partners and FNMPC members. In working with these companies, FNMPC will further advance strategies that promote meaningful Indigenous inclusion in major developments and articulate Indigenous perspectives concerning environmental, social and governance (ESG) investment standards and sustainable business practices generally.

“The commitment made by Cenovus supports FNMPC in its efforts to create pathways for reconciliation and enhance the economic well-being of our members,” says Chief Sharleen Gale, Chair of FNMPC. “Our Sustaining Partners support our most important work. FNMPC is pleased to be working closely with a select group of private sector organizations who share our vision for meaningful Indigenous inclusion in the economic mainstream of Canada.”

“Investing and working with Indigenous communities and businesses near our operations to ensure they share in the benefits of resource development has always been a key part of how we do business,” said Rhona DelFrari, Cenovus’s Chief Sustainability Officer & Senior Vice-President, Stakeholder Engagement. “We recognize our responsibility to support reconciliation with Indigenous people and look forward to working with the FNMPC, participating First Nations communities and fellow members of the Sustaining Partners Program to help advance Indigenous economic self-sustainability.”

As a Sustaining Partner, Cenovus will participate in FNMPC’s annual conference and benefit from an exclusive working relationship with FNMPC, specifically designed to advance stronger business relationships with Indigenous communities outside of a project-specific environment. For more information on the program, please contact Niilo Edwards, FNMPC’s Chief Executive Officer at [email protected].

About FNMPC:


The First Nations Major Projects Coalition (FNMPC) is a non-profit organization comprised of 90+ Indigenous communities that span across Canada. FNMPC members recognize that we are stronger together and was established to promote the shared interests of our members. Advancing major projects is the core of FNMPC’s service delivery. FNMPC’s technical team is active in supporting our member communities with tools, capacity supports, and advice related to corporate structures and benefit sharing models, as well as tools to promote environmental protection and impact assessment.

About Cenovus Energy Inc:


Cenovus Energy Inc. is an integrated energy company with oil and natural gas production operations in Canada and the Asia Pacific region, and upgrading, refining and marketing operations in Canada and the United States. Cenovus is focused on managing its assets in a safe, innovative and cost-efficient manner, integrating environmental, social and governance considerations into its business plans. Cenovus common shares and common share purchase warrants are listed on the Toronto Stock Exchange and the New York Stock Exchange, and Cenovus’s preferred shares are listed on the Toronto Stock Exchange. For more information, visit cenovus.com.

Find Cenovus on Facebook, Twitter, LinkedIn, YouTube and Instagram.

NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) — Saratoga Investment Corp. (NYSE:SAR) (“Saratoga Investment” or “the Company”), a business development company, today announced that it has received notification from the Small Business Administration (the “SBA”) that the Company’s application for a third Small Business Investment Company (“SBIC”) license has been approved.

The new SBIC license will provide up to $175 million in additional long-term capital in the form of SBA-guaranteed debentures, subject to the issuance of a leverage commitment by the SBA. Under current SBIC regulations, for two or more SBICs under common control, the maximum amount of outstanding SBA debentures cannot exceed $350.0 million with at least $175.0 million in combined regulatory capital.  

“We are excited to continue to grow our relationship with the SBA through a third SBIC license,” said Christian L. Oberbeck, Chairman and Chief Executive Officer of Saratoga Investment. “We look forward to expanding upon our existing investments in support of the SBAs mission to provide growth capital to small businesses which are so important to our economy. Our SBA-guaranteed debentures are a great benefit to our capital structure, further enabling us to provide innovative and cost-effective solutions to the many smaller and middle market companies we finance. We are grateful to the SBA for their continued support of Saratoga. We continue to develop the size and quality of our management team, disciplined credit analysis and robust investment sourcing pipeline. We will continue to apply consistent investment principles as we deploy the additional capital being made available to us with this third SBIC license.”

About Saratoga Investment

Saratoga Investment Corp. is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests primarily in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors.  Saratoga Investment Corp.’s objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.  Saratoga Investment Corp. has elected to be regulated as a business development company under the Investment Company Act of 1940 and is externally managed by Saratoga Investment Advisors, LLC, an SEC-registered investment advisor focusing on credit-driven strategies.  Saratoga Investment Corp. owns two SBIC-licensed subsidiaries and manages a $650 million collateralized loan obligation (“CLO”) fund and a joint venture (“JV”) fund.  It also owns 52% of the Class F and 100% of the subordinated notes of the CLO, and 87.5% of both the unsecured loans and membership interests of the JV.  The Company’s diverse funding sources, combined with a permanent capital base, enable Saratoga Investment Corp. to provide a broad range of financing solutions.

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements about the business and investments of Saratoga Investment, including the benefits of the SBIC license and SBA-guaranteed debentures. Forward-looking statements are statements that are not historical statements and can often be identified by words such as “will,” “believe,” “expect” and similar expressions and variations or negatives of these words. These statements are based on management’s current expectations, assumptions and beliefs. These forward-looking statements are subject to risks and uncertainties and other factors enumerated in this press release and the filings Saratoga Investment makes with the SEC. They are not guarantees of future results and are subject to numerous risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statement. Saratoga Investment undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact:
Henri Steenkamp
Saratoga Investment Corp.
212-906-7800

CHARLOTTE, N.C., Sept. 29, 2022 (GLOBE NEWSWIRE) — Strong Technical Services “(STS”), a wholly-owned subsidiary of Ballantyne Strong, Inc. (NYSE American: BTN) (“Ballantyne” or the “Company”), today announced that it has initiated a new digital content delivery offering for its cinema partners. Built on the Google Cloud global network, the offering enables STS customers to upload and distribute content from one convenient digital feed rather than downloading content files from multiple file-hosting services. Content can also be placed directly on the customer’s TMS from the service.

“We are committed to helping our cinema partners streamline their operations and this upgraded technology drives efficiencies by providing one seamless content delivery option rather than the retrieval of content from different sources,” commented Ray Boegner, President of Strong Entertainment at Ballantyne Strong. “STS has led the way on many innovative technologies in the cinema services industry and we’re pleased to diversify our portfolio with the addition of digital content delivery. We are rolling this out to one of our exhibitor partners after successfully piloting at 20 locations and are now offering it to our broader customer base.”

About Ballantyne Strong, Inc. and Strong Technical Services, Inc.

Ballantyne Strong, Inc. is a diversified holding company with operations and investments across a broad range of industries. The Company’s Strong Entertainment business unit includes STRONG/MDI Screen Systems (www.strongmdi.com), the leading premium screen and projection coatings supplier in the world and Strong Technical Services (www.strong-tech.com), which provides comprehensive managed service offerings with 24/7/365 support nationwide to ensure solution uptime and availability. Ballantyne Strong also holds stakes in GreenFirst Forest Products Inc., Firefly, Inc, and FG Financial Group, Inc.

Forward-Looking Statements

In addition to the historical information included herein, this press release includes forward-looking statements, such as management’s expectations regarding its portfolio companies, the Company’s intent to pursue an initial public offering and separate listing of its Entertainment business, as well as future sales, the impact, length and severity of the COVID-19 pandemic, general economic recovery from the effects of the COVID-19 pandemic, and the adequacy of the actions taken in response to the pandemic, which involve a number of risks and uncertainties, including but not limited to those discussed in the “Risk Factors” section contained in Item 1A in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 24, 2022, and the following risks and uncertainties: the negative impact that the COVID-19 pandemic has already had, and may continue to have, on the Company’s business and financial condition; the impact on the global economy and supply chains of the ongoing military conflict in Ukraine and the sanctions related thereto; the Company’s ability to maintain and expand its revenue streams to compensate for the lower demand for the Company’s digital cinema products and installation services; potential interruptions of supplier relationships or higher prices charged by suppliers; the Company’s ability to successfully compete and introduce enhancements and new features that achieve market acceptance and that keep pace with technological developments; the Company’s ability to successfully execute its capital allocation strategy or achieve the returns it expects from these investments; the Company’s ability to maintain its brand and reputation and retain or replace its significant customers; challenges associated with the Company’s long sales cycles; the impact of a challenging global economic environment or a downturn in the markets (such as the current economic disruption and market volatility generated by the ongoing COVID-19 pandemic and ongoing military conflict in Ukraine and related sanctions); economic and political risks of selling products in foreign countries (including tariffs); risks of non-compliance with U.S. and foreign laws and regulations, potential sales tax collections and claims for uncollected amounts; cybersecurity risks and risks of damage and interruptions of information technology systems; the Company’s ability to retain key members of management and successfully integrate new executives; the Company’s ability to complete acquisitions, strategic investments, entry into new lines of business, divestitures, mergers or other transactions on acceptable terms, or at all; the impact of the COVID-19 pandemic on the Company’s portfolio companies; the Company’s ability to utilize or assert its intellectual property rights, the impact of natural disasters and other catastrophic events (such as the ongoing COVID-19 pandemic and ongoing military conflict in Ukraine and related sanctions); the adequacy of insurance; the impact of having a controlling stockholder and vulnerability to fluctuation in the Company’s stock price. Given the risks and uncertainties, readers should not place undue reliance on any forward-looking statement and should recognize that the statements are predictions of future results which may not occur as anticipated. Many of the risks listed above have been, and may further be, exacerbated by the ongoing COVID-19 pandemic, its impact on the cinema and entertainment industry, and the worsening economic environment. Actual results could differ materially from those anticipated in the forward-looking statements and from historical results, due to the risks and uncertainties described herein, as well as others not now anticipated. New risk factors emerge from time to time and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Except where required by law, the Company assumes no obligation to update, withdraw or revise any forward-looking statements to reflect actual results or changes in factors or assumptions affecting such forward-looking statements.

For Investor Relations Inquiries:

IRVINE, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) — Today, ToughBuilt Industries, Inc. (“ToughBuilt”) (NASDAQ: TBLT; TBLTW) — has today announced major expansions to its network of storefronts in Great Britain, confirming broad new and expanding agreements with Huws Gray, Selco Builders Warehouse, MKM, City Electrical Factors, and Carpet & Flooring, magnifying the company’s online marketplace presence in Great Britain and representing more than 900 collective retail locations across the country.

Huws Gray is the United Kingdom’s largest independent builder’s merchant. Supplying materials to professional and DIY end users alike, it operates over 300 storefronts that trade under various brand names, including Huws Gray, Buildbase, The Timber Group, Civils & Lintels, and Frontline.

Additionally, ToughBuilt welcomes Selco Builder’s Warehouse, the UK’s fastest growing builder’s merchant, who distributes to construction professionals nationwide with a network of more than 73 outlets set to reach 100 locations by the end of 2026. As well as MKM, a building, timber, and plumbing supplies provider with more than 90 branches across England, Scotland, and Wales, and Carpet & Flooring, one of Britain’s largest flooring retailers and winner of the Contract Flooring Journal distributor of the year 3 years in a row.

ToughBuilt is also pleased to work with City Electrical Factors (CEF), the United Kingdom’s leading electrical wholesaler network. Beginning with a single storefront in Coventry in 1951, CEF has grown to more than 400 locations nationwide.

ToughBuilt CEO Michael Panosian stated, “ToughBuilt is growing rapidly in the United Kingdom, and we are pleased to expand our distribution network by nearly 900 storefronts across Great Britain. We are confident that this increased presence in the country will continue to grow our substantial market share and promote continued awareness of our brand’s commitment to premium quality products.”

ABOUT TOUGHBUILT INDUSTRIES, INC:
ToughBuilt is an advanced product design, manufacturer and distributor with emphasis on innovative products. Currently, we are focused on tools and other accessories for the professional and do-it-yourself construction industries. We market and distribute various home improvement and construction product lines for both the do-it-yourself and professional markets under the TOUGHBUILT brand name, within the global multibillion dollar per year tool market industry. All of our products are designed by our in-house design team. Since launching product sales in 2013, we have experienced significant annual sales growth. Our current product line includes three major categories, with several additional categories in various stages of development, consisting of Soft Goods & Kneepads and Sawhorses & Work Products. Our mission is to provide products to the building and home improvement communities that are innovative, of superior quality derived in part from enlightened creativity for our end users while enhancing performance, improving well-being and building high brand loyalty. Additional information about the Company is available at: https://www.toughbuilt.com/.

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the impact of the worldwide COVID-19 pandemic and government actions, on our business, (ii) supply chain disruptions, (iii) market acceptance of our existing and new products, (iv) delays in bringing products to key markets, (v) an inability to secure regulatory approvals for the ability to sell our products in certain markets, (vi) intense competition in the industry from much larger, multinational companies, (v) product liability claims, (vii) product malfunctions, (viii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) our reliance on single suppliers for certain product components, (xi) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Relations Contact:
KCSA Strategic Communications
David Hanover
[email protected]

Source: ToughBuilt Industries, Inc

Demodex blepharitis is a highly prevalent, yet often missed or misdiagnosed lid margin disease that impacts approximately 25 million eye care patients in the U.S.

IRVINE, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the launch of the “Look at the Lids” disease education campaign for Demodex blepharitis, a common lid margin disease that can negatively impact patients’ daily activities and eyelid health. The novel campaign is designed to encourage eye care professionals to screen for Demodex blepharitis in all eye care patients to identify and diagnose the disease sooner. The campaign will be unveiled at the 2022 American Academy of Ophthalmology (AAO) Annual Meeting in Chicago and the American Academy of Optometry (AAOpt) Annual Meeting in San Diego. “Look at the Lids” features real Demodex blepharitis patients and will include educational tools and resources for eye care professionals, including an informative website (www.LookattheLids.com), social media channels, webinars, launch events, and interactive activities at the Academy conferences.

“We’re thrilled to launch this truly unique disease education campaign for Demodex blepharitis, a pervasive and damaging eye disease that is commonly overlooked,” said Aziz Mottiwala, Chief Commercial Officer of Tarsus. “The goal of this campaign is to support eye care professionals so they can confidently and more frequently diagnose patients. Tarsus is committed to elevating eyelid health, and we look forward to bringing more awareness to this disease that negatively impacts so many patients.”

Approximately 25 million eye care patients in the United States have Demodex blepharitis, a lid margin disease characterized by eyelid inflammation, redness, and ocular irritation. The disease is caused by an infestation of Demodex mites, the most common ectoparasite found on humans. Collarettes, the cylindrical waxy debris composed of mite waste products and eggs on the eyelashes, are the pathognomonic sign of Demodex blepharitis, and can be identified by an eye care professional when a patient looks down during a slit lamp exam. One hundred percent of patients with collarettes have Demodex blepharitis.

“Demodex blepharitis, though extremely common, can masquerade as ocular allergies or dry eye disease since the symptoms are often similar,” said Eric Donnenfeld, MD, Cornea, Laser Cataract & Refractive Surgeon at OCLI Vision in New York. “The disease can be missed unless an eye care professional is specifically looking for the presence of collarettes, the sure sign of Demodex blepharitis. Fortunately, identifying collarettes is a simple step achieved by asking a patient to look down during a routine eye exam. I see Demodex in my practice daily, and I am encouraged that there is a campaign that will bring more visibility to this disease and assist other clinicians in their efforts to improve eyelid health.”

At both Academy meetings, “Look at the Lids” will have an interactive exhibit booth featuring a custom photo activation that allows eye care professionals to showcase their commitment to eyelid health by adding their own eyelid photo to a real-time updated video wall. The campaign will also feature launch events and interactive activities, all designed to provide disease education.

“It is remarkable how many patients I discover who have Demodex just by examining their lashes when they look down during a regular eye exam,” said Selina McGee, OD, FAAO, CEO of BeSpoke Vision in Oklahoma. “This disease is often hiding in plain sight, and without properly screening for it, many patients go undiagnosed. Demodex can cause damage and discomfort when left untreated, and I’m excited to be a part of a campaign designed to increase the identification and diagnosis of this very common disease.”

Eye care professionals can subscribe to the Collarette Coalition email list and be the first to receive the latest news and information on Demodex blepharitis at www.LookattheLids.com. The website also allows eye care professionals to submit their own photos and videos to the ‘Lid Gallery.’ Additionally, they can share their own Demodex blepharitis stories with the eye care community on social media by using #LookattheLids and following and tagging @lookatthelids on Instagram and Twitter.

In concert with the campaign – and as part of Tarsus’ commitment to education and innovation in eye care – the company will provide a donation to both the American Academy of Ophthalmology Foundation and the American Academy of Optometry Foundation.

About

Demodex

Blepharitis

Blepharitis is a common lid margin disease that is characterized by eyelid margin inflammation, redness and ocular irritation. Demodex blepharitis is caused by an infestation of Demodex mites, the most common ectoparasite found on humans and accounts for over two-thirds of all blepharitis cases. Demodex blepharitis may affect as many as 25 million Americans based on an extrapolation from the Titan study indicating 58% of patients presenting to U.S. eye care clinics have collarettes, a pathognomonic sign of Demodex infestation, and that at least 45 million people annually visit an eye care clinic. Demodex blepharitis can have a significant clinical burden and negative impact on patients’ daily lives. The Titan study also showed that current management tools, such as tea tree oil and lid wipes, are ineffective at treating Demodex blepharitis. Currently, there are no FDA-approved treatments for Demodex blepharitis.

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. Tarsus is studying two investigational medicines in clinical trials. Its lead product candidate, TP-03, is a novel therapeutic which has demonstrated positive results in two pivotal trials for the treatment of Demodex blepharitis, and of which a New Drug Application has been submitted to the U.S. Food & Drug Administration (FDA). TP-03 is also being developed for the treatment of Meibomian Gland Disease, and currently being studied in a Phase 2a clinical trial. In addition, Tarsus is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in a Phase 1b clinical trial.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include statements regarding the potential market size for TP-03, future events and Tarsus’ plans for and the anticipated benefits of its product candidates including TP-03 and TP-05, the timing, objectives and results of the clinical trials, anticipated regulatory and development milestones, and the quotations of Tarsus’ management and consultants. The words, without limitation, “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Further, there are other risks and uncertainties that could cause actual results to differ from those set forth in the forward-looking statement and they are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, including Tarsus’ Form 10-K for the year ended December 31, 2021 filed on March 14, 2022 and the most recent Form 10-Q quarterly filing filed with the SEC on August 11, 2022, each of which Tarsus incorporates by reference into this press release, copies of which are posted on its website and are available from Tarsus without charge. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release are based on the current expectations of Tarsus’ management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts:

Media Contact:

Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
[email protected]

Investor Contact:

David Nakasone
Head of Investor Relations
(949) 620-3223
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8a55faf1-5038-425d-85da-0325acdb2c0a

DENVER, Sept. 29, 2022 (GLOBE NEWSWIRE) — Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative neuromonitoring (“IONM”) and remote neurology services, announced that management will participate in the following investor conferences in October 2022:

• Roth Healthcare Opportunities Conference on October 6, 2022, in New York, NY. This invitation only event provides a forum for public healthcare companies to tell their stories to investors. The conference will consist of a 10-minute company presentation to the attendee audience, as well as one-on-one investor meetings.
• MicroCap Rodeo Windy City Roundup on October 12-13, 2022, in Chicago, IL. More than 60 microcap companies will meet with institutional investors, family offices and high net worth retail investors. Assure’s executive chairman and CEO John Farlinger is scheduled to present on October 12th at 12:00 p.m. ET with one-on-one meetings held throughout the conference. To receive additional information, request an invitation, or schedule a one-on-one meeting, please email [email protected].
• LD Micro Main Event on October 25-26, 2022, in Los Angeles, CA. The event will showcase over 200 small- and micro-cap companies. Assure’s CFO John Price is scheduled to present on October 26th at 3:30 p.m. ET with one-on-one meetings held throughout the conference.
• ThinkEquity Conference on October 26, 2022, in New York, NY. The ThinkEquity Conference brings together companies in the technology, healthcare, finance, and energy industries with institutional and accredited investors. Assure’s executive chairman and CEO John Farlinger is scheduled to present at 11:00 a.m. ET with one-on-one meetings held throughout the day.

Events with webcasted central presentations will be available live at https://ir.assureneuromonitoring.com/news-events/ir-calendar and available for replay after the live event.

About Assure Holdings

Assure Holdings Corp. is a best-in-class provider of outsourced intraoperative neuromonitoring and remote neurology services. The Company delivers a turnkey suite of clinical and operational services to support surgeons and medical facilities during invasive procedures that place the nervous system at risk including neurosurgery, spine, cardiovascular, orthopedic and ear, nose and throat surgeries. Assure employs highly trained technologists that provide a direct point of contact in the operating room. Physicians employed through Assure subsidiaries simultaneously monitor the functional integrity of patients’ neural structures throughout the procedure communicating in real-time with the surgeon and technologist. Accredited by The Joint Commission, Assure’s mission is to provide exceptional surgical care and a positive patient experience. For more information, visit the company’s website at www.assureneuromonitoring.com.

Forward-Looking Statements

This news release may contain “forward-looking statements” within the meaning of applicable securities laws, including, but not limited to comments with respect to: expectations with respect to the Company’s growth and development and the quality and results of future services. Forward-looking statements may generally be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainty surrounding the spread of COVID-19 and the impact it will have on the Company’s operations and business, its remote neurology business, and economic activity in general; and risks and uncertainties discussed in our most recent annual and quarterly reports filed with the United States Securities and Exchange Commission, including our annual report on Form 10-K filed on March 14, 2022, and available on the Company’s EDGAR profile at www.sec.gov, which risks and uncertainties are incorporated herein by reference. Except as required by law, Assure does not intend, and undertakes no obligation, to update any forward-looking statements to reflect, in particular, new information or future events.

Contact

Scott Kozak, Investor and Media Relations
Assure Holdings Corp.
1-720-617-2526
[email protected]